Patents by Inventor Gilbert Andre
Gilbert Andre has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11959088Abstract: A method for synthesizing a protein of interest within a plant or a portion of a plant is provided. The method involves treating the plant to increase secondary leaf biomass production, followed by introducing one or more than one nucleic acid sequence encoding a protein of interest operatively linked with a regulatory region that is active in the plant, into the plant. The plant is then maintained under conditions that permit the nucleic acid sequence encoding the protein of interest to be expressed in the plant or the portion of the plant. Optionally, the plant or portion of the plant may be harvested and the protein of interest extracted.Type: GrantFiled: July 10, 2015Date of Patent: April 16, 2024Assignees: ARAMIS BIOTECHNOLOGIES INC., UNIVERSITE LAVALInventors: Dominique Michaud, Steeve Pepin, Gilbert Ethier, Marie-Claire Goulet, Linda Gaudreau, Marielle Gagne, Michele Martel, Nicole Bechtold, Marc-Andre D'Aoust, Andre Gosselin
-
Publication number: 20130022539Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr115) antibodies that bind to Ovr115 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Ovr115 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr115 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr115 antibodies. The invention encompasses a method of producing the anti-Ovr115 antibodies. Other aspects of the invention are a method of killing an Ovr115-expressing cancer cell, comprising contacting the cancer cell with an anti-Ovr115 antibody and a method of alleviating or treating an Ovr115-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Ovr115 antibody to the mammal.Type: ApplicationFiled: June 14, 2012Publication date: January 24, 2013Applicant: diaDexus, Inc.Inventors: Glenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Laura Corral, Iris Simon
-
Publication number: 20120263647Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Pro104) antibodies that bind to Pro104 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Pro104 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro104 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro104 antibodies. The invention encompasses a method of producing the anti-Pro104 antibodies. Other aspects of the invention are a method of killing a Pro104-expressing cancer cell, comprising contacting the cancer cell with an anti-Pro104 antibody and a method of alleviating or treating a Pro104-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Pro104 antibody to the mammal.Type: ApplicationFiled: December 16, 2011Publication date: October 18, 2012Applicant: diaDexus, Inc.Inventors: Jackie Papkoff, Glenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Laura Corral, Iris Simon, Muriel Kmet, Jianwen Tang
-
Patent number: 8207311Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr115) antibodies that bind to Ovr115 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Ovr115 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr115 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr115 antibodies. The invention encompasses a method of producing the anti-Ovr115 antibodies. Other aspects of the invention are a method of killing an Ovr115-expressing cancer cell, comprising contacting the cancer cell with an anti-Ovr115 antibody and a method of alleviating or treating an Ovr115-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Ovr115 antibody to the mammal.Type: GrantFiled: May 17, 2004Date of Patent: June 26, 2012Assignee: diaDexus, Inc.Inventors: Glenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Laura Corral, Iris Simon
-
Patent number: 8080650Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Pro104) antibodies that bind to Pro104 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Pro104 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro104 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro104 antibodies. The invention encompasses a method of producing the anti-Pro104 antibodies. Other aspects of the invention are a method of killing a Pro104-expressing cancer cell, comprising contacting the cancer cell with an anti-Pro104 antibody and a method of alleviating or treating a Pro104-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Pro104 antibody to the mammal.Type: GrantFiled: January 15, 2009Date of Patent: December 20, 2011Assignee: diaDexus, Inc.Inventors: Jackie Papkoff, Glenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Laura Corral, Iris Simon, Muriel Kmet, Jianwen Tang
-
Publication number: 20100209438Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr110) antibodies that internalize upon binding to Ovr110 on a mammalian in vivo. The invention also encompasses compositions comprising an anti-Ovr110 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr110 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr110 antibodies. The invention encompasses a method of producing the anti-Ovr110 antibodies. Other aspects of the invention are a method of killing an Ovr110-expressing cancer cell, comprising contacting the cancer cell with an anti-Ovr110 antibody and a method of alleviating or treating an Ovr110-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Ovr110 antibody to the mammal.Type: ApplicationFiled: October 9, 2009Publication date: August 19, 2010Inventors: Glenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Laura Corral, Iris Simon, Jackie Papkoff
-
Patent number: 7658591Abstract: A layout for cooling a blade having a cavity surrounded by an internal wall including cooling fins which are spaced apart from each other by a pitch (p) and each have a thickness (e). The blade has, inside the cavity, a jacket passed through by emission holes each having a diameter (d). When the jacket is in place in the cavity of the blade, and in respect of the critical operating point of the turbine engine, each emission hole of the jacket is opposite a place on the internal wall of the blade which is located between cooling fins.Type: GrantFiled: November 6, 2006Date of Patent: February 9, 2010Assignee: SNECMAInventors: Alexandre Dervaux, Jean-Michel Bernard Guimbard, Damien Gilbert Andre Redon, Pascal Bertrand Yves Claude Papot
-
Patent number: 7619068Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr110) antibodies that internalize upon binding to Ovr110 on a mammalian in vivo. The invention also encompasses compositions comprising an anti-Ovr110 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr110 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr110 antibodies. The invention encompasses a method of producing the anti-Ovr110 antibodies. Other aspects of the invention are a method of killing an Ovr110-expressing cancer cell, comprising contacting the cancer cell with an anti-Ovr110 antibody and a method of alleviating or treating an Ovr110-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Ovr110 antibody to the mammal.Type: GrantFiled: May 10, 2004Date of Patent: November 17, 2009Assignee: diaDexus, Inc.Inventors: Glenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Laura Corral, Iris Simon, Jackie Papkoff
-
Publication number: 20090220424Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Pro104) antibodies that bind to Pro104 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Pro104 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro104 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro104 antibodies. The invention encompasses a method of producing the anti-Pro104 antibodies. Other aspects of the invention are a method of killing a Pro104-expressing cancer cell, comprising contacting the cancer cell with an anti-Pro104 antibody and a method of alleviating or treating a Pro104-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Pro104 antibody to the mammal.Type: ApplicationFiled: January 15, 2009Publication date: September 3, 2009Inventors: Jackie Papkoff, Glenn Pilkington, Gilbert-Andre Keller, Weniu Li, Laura Corral, Iris Simon, Muriel Kmet, Jianwen Tang
-
Publication number: 20090136490Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr110) antibodies that internalize upon binding to Ovr110 on a mammalian in vivo. The invention also encompasses compositions comprising an anti-Ovr110 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr110 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr110 antibodies. The invention encompasses a method of producing the anti-Ovr110 antibodies. Other aspects of the invention are a method of killing an Ovr110-expressing cancer cell, comprising contacting the cancer cell with an anti-Ovr110 antibody and a method of alleviating or treating an Ovr110 expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Ovr110 antibody to the mammal.Type: ApplicationFiled: November 10, 2005Publication date: May 28, 2009Applicant: DIADEXUS, INC.Inventors: Glenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Timothy S. Burcham, Laura Corral, Iris Simon, Jackie Papkoff
-
Patent number: 7479546Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Pro104) antibodies that bind to Pro 104 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Pro104 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro 104 antibody, as well as an expression vector comprising the isolated'l nucleic acid. Also provided are cells that produce the anti-Pro 104 antibodies. The invention encompasses a method of producing the anti-Pro 104 antibodies. Other aspects of the invention are a method of killing a Pro 104-expressing cancer cell, comprising contacting the cancer cell with an antiPro104 antibody and a method of alleviating or treating a Pro 104-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Pro 104 antibody to the mammal.Type: GrantFiled: June 28, 2004Date of Patent: January 20, 2009Assignee: diaDexus, Inc.Inventors: Jackie Papkoff, Glenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Laura Corral, Iris Simon, Muriel Kmet, Jianwen Tang
-
Patent number: 7435416Abstract: The invention provides antibodies targeted at a tumor antigen prevalent on prostate tumors and methods useful in alleviating cancers expressing the antigen, as well as nucleic acids and cells for expressing the antibodies.Type: GrantFiled: September 8, 2004Date of Patent: October 14, 2008Assignee: Genetech, Inc.Inventors: Brigitte Devaux, Gilbert-Andre Keller, Hartmut Koeppen, Lawrence A. Lasky
-
Publication number: 20070178101Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr110) antibodies that internalize upon binding to Ovr110 on a mammalian in vivo. The invention also encompasses compositions comprising an anti-Ovr110 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr110 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr110 antibodies. The invention encompasses a method of producing the anti-Ovr110 antibodies. Other aspects of the invention are a method of killing an Ovr110-expressing cancer cell, comprising contacting the cancer cell with an anti-Ovr110 antibody and a method of alleviating or treating an Ovr110-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Ovr110 antibody to the mammal.Type: ApplicationFiled: May 10, 2004Publication date: August 2, 2007Inventors: Glenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Laura Corral, Iris Simon, Jackie Papkoff
-
Publication number: 20070104647Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr115) antibodies that bind to Ovr115 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Ovr115 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr115 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr115 antibodies. The invention encompasses a method of producing the anti-Ovr115 antibodies. Other aspects of the invention are a method of killing an Ovr115-expressing cancer cell, comprising contacting the cancer cell with an anti-Ovr115 antibody and a method of alleviating or treating an Ovr115-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Ovr115 antibody to the mammal.Type: ApplicationFiled: May 17, 2004Publication date: May 10, 2007Inventors: Glenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Laura Corral, Iris Simon
-
Publication number: 20070087004Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Pro104) antibodies that bind to Pro 104 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Pro104 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro 104 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro 104 antibodies. The invention encompasses a method of producing the anti-Pro 104 antibodies. Other aspects of the invention are a method of killing a Pro 104-expressing cancer cell, comprising contacting the cancer cell with an antiPro104 antibody and a method of alleviating or treating a Pro 104-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Pr 104 antibody to the mammal.Type: ApplicationFiled: June 28, 2004Publication date: April 19, 2007Inventors: Jackie Papkoff, Glenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Laura Corral
-
Patent number: 7099474Abstract: A key and lock device comprises a key having a first electronic circuit and a lock having a second electronic circuit. The key and the lock store secret information, some of which is unique for each device. The key and the lock exchange a random number through connectors and perform a calculation in the respective circuitry based on the random number and secret information. An electrical blocking mechanism is moved to a non-blocking position if a comparison of the calculations in the circuits gives the correct result.Type: GrantFiled: May 5, 2000Date of Patent: August 29, 2006Assignee: Assa Abby ABInventors: Inge Lidén, Rolf Norberg, Björn Magnusson, Johan Warnström, Reijo Hakkarainen, Hannu Sivonen, Gudrun Brennecke, Christophe Chanel, Jens Gürtler, Jürgen Krühn, Alain Varenne, J M Thomas, Lance Schoell, Gilbert Andre, Christian Darmanin, Arnaud Lefebvre, Walter Hammer, Claude-Eric Jaquet, Nicolas Peguiron
-
Publication number: 20050036942Abstract: The invention provides antibodies targeted at a tumor antigen prevalent on prostate tumors and methods useful in alleviating cancers expressing the antigen, as well as nucleic acids and cells for expressing the antibodies.Type: ApplicationFiled: September 8, 2004Publication date: February 17, 2005Applicant: Genentech, Inc.Inventors: Brigitte Devaux, Gilbert-Andre Keller, Hartmut Koeppen, Lawrence Lasky
-
Patent number: 6824780Abstract: The invention provides antibodies targeted at a tumor antigen prevalent on prostate tumors and methods useful in alleviating cancers expressing the antigen, as well as nucleic acids and cells for expressing the antibodies.Type: GrantFiled: October 27, 2000Date of Patent: November 30, 2004Assignee: Genentech, Inc.Inventors: Brigitte Devaux, Gilbert-Andre Keller, Hartmut Koeppen, Lawrence A. Lasky